This week in therapeutics




Licensing status

Publication and contact information


Head and neck cancer

CXC chemokine receptor 7 (CXCR7)

Mouse studies suggest CXCR7-targeting nanobodies could help treat head and neck cancers. In a xenograft mouse model of CXCR7+ human head and neck squamous cell carcinoma, injection of a CXCR7-targeting nanobody decreased tumor growth compared with saline injection. Next steps could include evaluating the CXCR7-targeting nanobody in additional head and neck cancer models.
Ablynx N.V. collaborated on the study and has multiple nanobodies in clinical and preclinical development for various diseases. The company has not disclosed if there is a CXCR7-targeting nanobody in its pipeline.
ChemoCentryx Inc.'s CCX650, a small molecule CXCR7 antagonist, is in preclinical development to treat brain cancer.

SciBX 6(37); doi:10.1038/scibx.2013.1027
Published online Sept. 26, 2013

Patent and licensing status unavailable

Maussang, D. et al. J. Biol. Chem.; published online Aug. 26, 2013;
Contact: Martine J. Smit, Free University Amsterdam, Amsterdam, the Netherlands